Veiligheid en werkzaamheid van tauroursodeoxycholisch zuur (TUDCA) als toegevoegde behandeling bij patiënten die lijden aan amyotrofische laterale sclerose (ALS). KU Leuven
TUDCA-ALS will focus on amyotrophic lateral sclerosis (ALS) a rare neurodegenerative disorder, that affects motor neurons in the brain, brainstem and spinal cord, resulting in progressive weakness and atrophy of voluntary skeletal muscles. ALS has an estimated prevalence of 5.40 cases per 100.000 population corresponding at about 40.000 patients at European level. Treatments are modestly effective at best, and the majority of patients die ...